12:00 AM
 | 
Aug 23, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bremelanotide: Phase I data

In a double-blind, placebo-controlled, crossover Phase I trial in 49 healthy male volunteers ages 45-65, subcutaneous bremelanotide achieved therapeutic blood plasma levels with no sustained clinically significant effects on blood pressure. Palatin plans to meet with...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >